Most-Upgraded StocksMost-UpgradedNASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis $274.46 +4.09 (+1.51%) (As of 05:18 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Alnylam Pharmaceuticals alerts: Email Address About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ALNY alerts:Sign Up Key Stats Today's Range$270.24▼$274.5750-Day Range$233.81▼$287.0152-Week Range$141.98▼$287.55Volume758,107 shsAverage Volume891,904 shsMarket Capitalization$34.72 billionP/E RatioN/ADividend YieldN/APrice Target$279.14Consensus RatingModerate Buy Company OverviewAlnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More… We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Alnylam Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 87th PercentileAlnylam Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 163rd out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 17 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alnylam Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($2.73) to ($2.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -101.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -101.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Alnylam Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.98% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently decreased by 16.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.52 Percentage of Shares Shorted2.98% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently decreased by 16.59%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.90 News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Alnylam Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 6 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows5 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,658,824.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alnylam Pharmaceuticals' insider trading history. Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Stock News HeadlinesAlnylam Stock Soars 65%: Find Out What’s Behind the GainsAlnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug.September 12, 2024 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 15,000 SharesAugust 23, 2024 | insidertrades.comWhy Are Buffett, Bezos, and Musk Fleeing Tech? Here's What To Do Now...The financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumping their tech stocks at a pace we've never seen before. What do they know that's pushing them out? One that Fortune is calling:"The Great Cash Out".September 17, 2024 | InvestorPlace (Ad)Alnylam Pharma (ALNY) Receives a Buy from Bank of America SecuritiesSeptember 16 at 7:39 PM | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Alnylam Pharma (ALNY)September 16 at 7:39 PM | markets.businessinsider.comInnate Pharma (IPHA) Receives a Buy from Evercore ISISeptember 16 at 5:08 AM | markets.businessinsider.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Decline in Short InterestSeptember 16 at 3:01 AM | americanbankingnews.comInhibrx: The Biotech Spinoff Poised For Big GainsSeptember 16 at 12:07 AM | forbes.comSee More Headlines ALNY Stock Analysis - Frequently Asked Questions How have ALNY shares performed this year? Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of the year. Since then, ALNY shares have increased by 42.4% and is now trading at $272.50. View the best growth stocks for 2024 here. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. Alnylam Pharmaceuticals's revenue was up 107.0% on a year-over-year basis. Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' top institutional shareholders include Baillie Gifford & Co. (4.77%), American Century Companies Inc. (1.07%), TD Asset Management Inc (0.39%) and Susquehanna International Group LLP. Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Akshay Vaishnaw, Michael W Bonney, Pushkal Garg, Kevin Joseph Fitzgerald, Amy W Schulman, Tolga Tanguler, Steven M Paul, Dennis A Ausiello, David E I Pyott, Indrani Lall Franchini and John Maraganore. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Mylan (MYL). Company Calendar Last Earnings8/01/2024Today9/17/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$279.14 High Stock Price Target$400.00 Low Stock Price Target$159.00 Potential Upside/Downside+3.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-3.11% Pretax Margin-2.63% Return on EquityN/A Return on Assets-1.88% Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio2.93 Sales & Book Value Annual Sales$2.34 billion Price / Sales14.59 Cash FlowN/A Price / Cash FlowN/A Book Value($1.76) per share Price / Book-153.62Miscellaneous Outstanding Shares126,492,000Free Float124,595,000Market Cap$34.20 billion OptionableOptionable Beta0.38 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 10, 2024. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com. Alnylam Pharmaceuticals Bull Case Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.: Alnylam Pharmaceuticals, Inc. has had its price target raised to $280.00 by JPMorgan Chase & Co., indicating potential growth. Multiple equities research analysts have given Alnylam Pharmaceuticals, Inc. a "buy" rating, suggesting positive market sentiment. Institutional investors like Vanguard Group Inc. and Price T Rowe Associates Inc. MD have increased their holdings in Alnylam Pharmaceuticals, Inc., showing confidence in the company's future prospects. The company's stock price has been on an upward trend, reaching a 12-month high of $285.00, indicating strong performance. Alnylam Pharmaceuticals, Inc. focuses on developing novel therapeutics based on ribonucleic acid interference, which represents cutting-edge technology in the biopharmaceutical industry. Alnylam Pharmaceuticals Bear Case Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons: Alnylam Pharmaceuticals, Inc. has a negative PE ratio of -101.07, which may indicate overvaluation or financial instability. The company's stock experienced a 1.3% decline, suggesting potential volatility in the market. Insiders have sold a significant number of shares in the last 90 days, raising concerns about internal confidence in the company. Alnylam Pharmaceuticals, Inc. has a beta of 0.37, indicating lower volatility compared to the market average, which may limit potential returns for investors seeking higher risk-reward opportunities. While the company has received positive ratings from analysts, the consensus rating of "Moderate Buy" may not reflect strong conviction in the stock's performance. This page (NASDAQ:ALNY) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Boeing Disasters Could Impact NvidiaHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrillion Dollar Blockchain Shift Could Trigger THIS CoinIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free alny Stock Alerts